Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP)

REHOVOT, Israel and NEW BRUNSWICK, New Jersey, April 20 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), announced today that it has presented updated results on its lead diagnostic development program for cancer of unknown primary (CUP), at the Annual Meeting of the American Association for Cancer Research (AACR), in Los Angeles, California.

The poster, titled "MicroRNA Signature for Identification of Tumor Origin" presented the expansion of the company's CUP assay to include 15 major cancer types, identifiable through a unique signature of 19 microRNAs with 85% accuracy. In addition, data was presented regarding Rosetta Genomics' proprietary methods for extraction and profiling of microRNAs.

The poster is available for viewing on the company's web site through the following link:

http://www.rosettagenomics.com/_Uploads/UtilsMedia/AACR_April2007.jpg

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

About Rosetta Genomics

Rosetta Genomics (NASDAQ: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of miRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the possible identification of a novel diagnostics approach for targeting miRNAs, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's most recent Registration Statement on Form F-1 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

    
    Contact: Media & Investors
    Ron Kamienchick
    T: +972-8-948-4785
    Ron_Ka@RosettaGenomics.com